Ratings Theratechnologies Inc.

Equities

TH

CA88338H7040

Market Closed - Toronto S.E. Other stock markets 03:59:59 2024-07-09 pm EDT			5-day change	1st Jan Change
2.1 ^CAD	+10.53%		+10.53%	-1.87%

May. 23	Theratechnologies Up Near 5% In US After Hours On Data Related To Its Lead Investigational Peptide Drug Conjugate Candidate	MT
May. 23	Theratechnologies Brief: Says Sudocetaxel Zendusortide ASCO 2024 Presentation "Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors"	MT

Strengths

Sales forecast by analysts have been recently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.

Weaknesses

Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
THERATECHNOLOGIES INC.	-1.87%	64.08M	-
SAMSUNG BIOLOGICS CO.,LTD.	+4.74%	40.77B	A-
BIOGEN INC.	-11.48%	33.21B	B-
UCB	+82.45%	29.36B	A
BIOMARIN PHARMACEUTICAL INC.	-13.94%	15.7B	C
INCYTE CORPORATION	-3.33%	13.08B	B-
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-12.64%	11.39B	D+
ALTEOGEN INC.	+166.50%	10.47B	D
SWEDISH ORPHAN BIOVITRUM AB	+5.54%	9.08B	B+
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-57.32%	8.58B	B

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes